BRAF, MEK Inhibitor Combo Assessed in Resected Melanoma

This article originally appeared here.
Rate of relapse-free survival up for resected stage III melanoma with <i>BRAF</i> V600E, V600K mutations
Rate of relapse-free survival up for resected stage III melanoma with BRAF V600E, V600K mutations

HealthDay News — For patients with resected stage III melanoma with BRAF V600E or V600K mutations, adjuvant dabrafenib plus trametinib is associated with a higher rate of relapse-free survival, according to a study published online September 10 in the New England Journal of Medicine. The research was published to coincide with the European Society of Medical Oncology Congress, held from September 8 to 12 in Madrid.

Georgina V. Long, MB, BS, PhD, from the University of Sydney, and colleagues randomized 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib plus trametinib (438 patients) or two matched placebo tablets (432 patients) for 12 months. 

Related Articles

The researchers found that the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group at a median follow-up of 2.8 years (hazard ratio for relapse or death, 0.47; 95% confidence interval, 0.39 to 0.58; P<0.001). The 3-year overall survival rate was 86 and 77% in the combination-therapy and placebo groups (hazard ratio for death, 0.57; 95% confidence interval, 0.42 to 0.79; P=0.0006); this did not cross the prespecified interim analysis boundary of P=0.000019. The combination-therapy group had higher rates of distant metastasis-free survival and freedom from relapse.

"The adjuvant use of dabrafenib plus trametinib resulted in a significantly lower rate of recurrence than the adjuvant use of placebo," the authors write.

The study was funded by GlaxoSmithKline and Novartis; Novartis manufactures dabrafenib and trametinib.

Abstract
Full Text (subscription or payment may be required)
More Information